TAT-10: Targeted Alpha Therapy of Glioblastoma Multiforme: Clinical Experience with Bi213 and Ac225-Substance P

Kanazawa, Japan (UroToday.com) Glioblastoma multiforme (GBM) is a common brain tumor in young men with a poor prognosis of 15 months even with aggressive treatment of surgery, chemotherapy, and external radiation. In this study, the radionuclide is bound in DOTA and linked to Substance P which targets NK1 receptors expressed by GBM. The  dose was administered by 1 or 2 catheters into  either the tumor or the cranial cavity through the scull penetration remaining from the surgical treatment. PET scan imaging from Ga68-SubstanceP co-injected into the tumor site verified high retention of the radio-isotope. 

The Bi213 group contained 18 primary GBM and 7 secondary GBM subjects. Patients were treated with 1-7 doses of 2 GBq. In patients with primary GBM, the progression-free survival from the start of alpha therapy was 3.7 months. The median overall survival was 21.5 months from diagnosis and 9 months from recurrence. In patients with secondary GBM, the median progression-free survival was 13.6 months. Median overall survival was 46.8 months from diagnosis.

The Ac225 arm had 5 primary GBM patients. They were treated with 1-4 doses of 10 MBq in intervals of about 2 months. Median overall survival was 34 months from diagnosis and 12 months from recurrence.

The targeted alpha therapy was safe and well tolerated with both isotopes.

Presented By: Leszek Krolicki from the Department of Nuclear Medicine, Medical University of Warsaw, Poland

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe